SENIOR APPOINTMENTS AT ASTRAZENECA AstraZeneca today announced the appointment of Bruno Angelici as Executive Vice President, International Sales and Marketing in succession to Mike O'Brien who is retiring.
ASTRAZENECA FILES ZOMIG® NASAL SPRAY IN EUROPE AstraZeneca announced today that it has submitted its first regulatory application in Europe for Zomig (zolmitriptan) Nasal Spray for the acute treatment of migraine with or without aura. This new treatment will be reviewed under the Mutual Recognition procedure with Sweden acting as the reference member state. This is the first filing of a second-generation triptan for a nasal spray formulation.
SYNGENTA SHARES PRICED AT CHF 85 FOR GLOBAL SECONDARY OFFERING Not for distribution or release in whole or in part into or from the United States, Canada, Australia or JapanAstraZeneca announces that AstraZeneca, Novartis, Syngenta and the Joint Global Co-ordinators have set a price of CHF 85 per share (equivalent to approximately £33.65 and 479.88 SEK per share) and USD 9.63 per ADS for the Global Secondary Offering of Syngenta shares. The price per ADS is based upon the noon buying rate of the New York Federal Reserve Bank on 10 November 2000 of CHF 1.7657 to USD 1.
This website is intended for people seeking information on AstraZeneca's International business. We also have national business sites; links to these are under 'Other AZ websites' at the top of the page.